The Billion-Dollar Shift: What Whistleblowers Need to Know About New HHS Priorities

The US Department of Health and Human Services (HHS) has recently signaled a significant shift in its enforcement priorities regarding whistleblower cases, particularly those involving fraud, waste, and abuse within federal healthcare programs. This heightened focus underscores a commitment to protecting taxpayer dollars, ensuring patient safety, and maintaining the integrity of the healthcare system. For whistleblowers, healthcare providers, and legal practitioners, understanding these evolving priorities is crucial. This blog post delves into the specifics of HHS’s renewed emphasis, its implications, and what stakeholders can expect in the coming years.

The Landscape of Healthcare Fraud: A Persistent Challenge

Healthcare fraud remains a colossal problem, costing the U.S. billions of dollars annually. These losses not only drain public funds but also compromise the quality of care, distort market competition, and erode public trust in healthcare institutions. Schemes can range from false billing and upcoding to medically unnecessary services, kickbacks, and elaborate conspiracies involving multiple entities.

The primary legal tool for combating healthcare fraud involving federal funds is the False Claims Act (FCA). The FCA allows private citizens (whistleblowers or “Relators”) with original information about fraud against the government to file a lawsuit on the government’s behalf. If successful, the whistleblower can receive a share of the government’s recovery. This mechanism has proven incredibly effective, with whistleblowers playing a pivotal role in recovering billions for the U.S. Treasury.

HHS’s Renewed Vigor: A Multi-pronged Approach

Under the current administration, HHS, in collaboration with the Department of Justice (DOJ), has articulated a clear strategy to intensify its efforts against healthcare fraud. This isn’t merely a continuation of past efforts but rather an enhanced, strategic approach built on several key pillars:

1. Data Analytics and Artificial Intelligence (AI)

One of the most significant shifts is the increased reliance on sophisticated data analytics and AI to identify potential fraud schemes. HHS agencies, like the Centers for Medicare & Medicaid Services (CMS) and the Office of Inspector General (OIG), are leveraging vast datasets to:

• Proactively Identify Anomalies: AI can detect unusual billing patterns, sudden spikes in specific procedures, or geographic clusters of suspicious activity that human analysts might miss.
• Identify Emerging Schemes: As fraudsters adapt, AI can help identify new types of schemes before they become widespread.
• Target High-Risk Providers: Data can pinpoint providers, organizations, or even entire sectors with a higher propensity for fraudulent activity, allowing for more focused investigations.

This data-driven approach means that providers who once thought their fraudulent activities were too small to notice are now increasingly at risk.

2. Focus on “Big Fish” and Systemic Fraud

While individual instances of fraud are still pursued, HHS is placing a greater emphasis on uncovering and prosecuting “big fish”—large corporations, healthcare systems, and individuals responsible for systemic, widespread fraud. The goal is to dismantle complex criminal enterprises that cause the most significant financial damage and undermine the healthcare system on a broad scale. This often involves:

• Corporate Accountability: Holding corporate executives and boards responsible for fostering environments where fraud can thrive, or for directly sanctioning fraudulent practices.
• Interagency Collaboration: Enhanced cooperation between HHS, DOJ, FBI, and other federal and state agencies to tackle intricate, multi-jurisdictional schemes.

3. Protecting Vulnerable Populations

A crucial ethical component of HHS’s new priority is safeguarding vulnerable populations. This includes the elderly, individuals with disabilities, and low-income communities who are often targets of healthcare fraud. Schemes such as:

• Unnecessary Medical Devices or Services: Marketing and providing medically unnecessary durable medical equipment (DME), genetic testing, or home healthcare services to vulnerable beneficiaries.
• Opioid and Substance Abuse Treatment Fraud: Exploiting individuals struggling with addiction by offering sham treatment programs, billing for services not rendered, or engaging in patient brokering.

HHS is committed to prosecuting those who prey on the most susceptible members of society, viewing such fraud not just as a financial crime but as an act that directly harms patients.

4. Telehealth and COVID-19 Related Fraud

The rapid expansion of telehealth services during the COVID-19 pandemic, while beneficial, also opened new avenues for fraud. HHS and its enforcement partners are actively pursuing cases related to:

• Billing for Services Not Rendered: Charging for telehealth consultations that never occurred.
• Fraudulent Prescribing: Illegally prescribing controlled substances via telehealth without proper medical evaluation.
• Exploiting Pandemic Relief Funds: Misusing funds from programs like the Provider Relief Fund or engaging in fraud related to COVID-19 testing, vaccines, and treatments.

The temporary flexibilities granted during the public health emergency are now being scrutinized, and providers are expected to adhere to strict compliance standards.

5. Whistleblower Engagement and Protection

Central to HHS’s strategy is the continued, and arguably enhanced, reliance on whistleblowers. The government recognizes that insiders often possess the most direct and compelling evidence of fraud. To encourage more individuals to come forward, HHS and DOJ are emphasizing:

• Protection Against Retaliation: Ensuring whistleblowers are protected from adverse employment actions for reporting fraud.
• Fair Compensation: Highlighting the financial incentives under the FCA for successful whistleblower actions.
• Streamlined Processes: Working to make the process of reporting fraud and cooperating with investigations as efficient as possible.

The message is clear: whistleblowers are invaluable partners in the fight against healthcare fraud, and their contributions are actively sought and protected.

Implications for Stakeholders

For Healthcare Providers and Organizations:

• Enhanced Compliance Programs: Now more than ever, robust and effective compliance programs are not just good practice but a necessity. These should include regular audits, thorough employee training, and clear channels for internal reporting of suspicious activities.
• Risk Assessments: Proactive risk assessments are critical to identify vulnerabilities to fraud, especially in areas identified as priorities by HHS (e.g., telehealth, certain medical devices, or specific service lines).
• Internal Investigations: When potential issues arise, conducting prompt and thorough internal investigations can demonstrate good faith and potentially mitigate penalties.
• Documentation is Key: Maintaining meticulous and accurate documentation for all services billed, medical necessity, and compliance efforts is paramount.

For Whistleblowers:

• Increased Government Interest: Whistleblower complaints aligned with HHS’s priorities are likely to receive closer scrutiny and potentially faster action from the government.
• The Importance of Specificity: While the government is eager to pursue fraud, whistleblowers still need to provide detailed, credible information. This often means working closely with experienced legal counsel to ensure the complaint meets the stringent requirements of the FCA and Federal Rule of Civil Procedure 9(b) (which demands particularity in fraud allegations).
• Legal Counsel is Essential: Engaging an attorney experienced in FCA litigation is crucial to navigate the complex legal landscape, protect your rights, and maximize the chances of a successful outcome.

Real World Examples

Recent enforcement actions from 2025 and early 2026 clearly illustrate the “new government priorities” for HHS. The data shows a massive shift toward Medicare Advantage, Artificial Intelligence (AI), and Telehealth, backed by record-breaking recoveries.

Here are specific examples and cases that reflect these changes:

1. The Medicare Advantage “Crackdown”

HHS has shifted its gaze toward “Managed Care” (Medicare Part C). Because these plans are paid based on the “risk scores” of patients, the government is now aggressively targeting “upcoding”—billing for severe illnesses that patients don’t actually have.

• Kaiser Permanente ($556 Million, Jan 2026): In one of the first major resolutions of 2026, Kaiser affiliates settled allegations that they submitted unsupported diagnosis codes to inflate Medicare Advantage payments. See United States ex rel. Osinek v. Kaiser Permanente, et al., No. 3:13-cv-03891 (N.D. Cal.); United States ex rel. Taylor v. Kaiser Permanente, et al., No. 3:21-cv-03894 (N.D. Cal.).
• Seoul Medical Group ($60 Million, 2025): This case targeted a medical group and its former president for allegedly submitting false diagnosis codes for spinal conditions to increase risk-adjustment payments. See U.S. ex rel. Pew v. Seoul Medical Group, Inc., et al., No. 2:20-cv-05156 (C.D. Cal.).

2. High-Tech Fraud: AI and Data Analytics

HHS is no longer just waiting for a whistleblower to call; they are using a “Data Fusion Center” to find the fraud themselves.

• The AI “Nudge” Case: The DOJ entered its first non-prosecution agreement involving a Medicare Advantage organization that used a proprietary AI platform to drive new enrollments through pharmacists in exchange for kickbacks.
• Wound Care Data Flagging: Using advanced analytics, HHS-OIG identified a seven-fold increase in Medicare Part B spending on skin substitute products (from $400M to nearly $3B in two years). This led to a $45 million settlement with Vohra Wound Physicians for medically unnecessary services. See United States v. Vohra Wound Physicians Mgmt., et al., Case No. 1:25-cv-21570-RKA (S.D. Fla. 2025).

3. The 2025 National Health Care Fraud Takedown

In June 2025, HHS and the DOJ executed the largest takedown in history, which serves as a roadmap for their current priorities:

• Total Scope: Over $14.6 billion in alleged losses and 324 defendants charged.
• Telehealth Focus: A major portion of this takedown, including “Operation Gold Rush,” targeted telemedicine schemes where doctors signed off on genetic tests and expensive braces for patients they never actually treated.

4. Protecting Vulnerable Populations

HHS has prioritized cases where fraud directly impacts patient safety or exploits the vulnerable.

• Cancer Genetic Testing Schemes: In 2025, the DOJ pursued a multistate scheme that targeted low-income individuals at public locations. Marketers used sham screening events to get DNA samples and then used “telemedicine orders” from doctors who had no relationship with the patients to bill Medicaid.  See United States v. Alshalabi, Case No. 3:21-cr-00171; United States v. Toh, Case No. 3:22-cr-00392.
• Cybersecurity as Fraud: In a new twist, Health Net Federal Services (Centene) paid $11.2 million in 2025 to resolve allegations of false cybersecurity certifications. HHS now views a failure to protect patient data as a “false claim” to the government.

Conclusion: A New Era of Enforcement

HHS’s sharpened focus on whistleblower cases represents a significant commitment to safeguarding federal healthcare programs. The synergistic application of advanced data analytics, a strategic emphasis on systemic fraud, the protection of vulnerable populations, and the continued empowerment of whistleblowers signals a new era of enforcement. For those within the healthcare ecosystem, this shift demands vigilance, proactive compliance, and a clear understanding of the heightened risks associated with fraudulent conduct. For whistleblowers, it presents a critical opportunity to contribute to justice, protect public funds, and play a vital role in ensuring the integrity of the U.S. healthcare system.